HORIBA Medical provides a comprehensive line of hematology, hemostasis, and clinical chemistry solutions (including analyzers, reagents, and consumables) for use in in-vitro diagnostics. These automated analyzers meet the needs of various users including patients, doctors, private laboratories, clinics and university hospitals. At HORIBA, we always cater to market requirements with the most cost-effective and highly advanced tech solutions for our customers.
HORIBA’s expertise in in-vitro diagnostics is amongst the most respected ones in the hematology segment worldwide. We have been providing a wide range of hematology analyzers from 3-part to 9-part to high-end systems. Our instruments are designed for all kinds of laboratories with small to high workloads.
After stamping the authority as a major hematology player, HORIBA Medical is now stepping into clinical chemistry with a complete range of product lines.
Clinical chemistry analyzers have been increasingly popular in recent decades because of major technological breakthroughs and expanding healthcare business demands. Fully automated clinical chemistry testing is becoming popular, pertaining to the increased testing volume and quicker processing times provided by them.
HORIBA’s acquisition of MedTest Holdings, Inc. which composes of MedTest Dx, Inc., Pointe Scientific, Inc., Clinitox Diagnostix, Inc., and Medical Laboratory Solutions, Inc. combines the complementary innovative technology offerings of HORIBA Medical with MedTest Dx technology, Clinitox, and Pointe Scientific’s R&D and manufacturing capabilities, with expertise in FDA 510K and CLIA clearances, to address the multidisciplinary requirements of IVD testing customers.
HORIBA Medical is coming up with the Yumizen C range (clinical chemistry analyzers), which will offer new levels of instrument and reagent synergy. The new Yumizen C range analyzers Yumizen C230, Yumizen C240, and Yumizen C560 will provide quick and reliable results, featuring robust hardware and advanced software – all backed by HORIBA Medical’s gold-standard service and support organization. These new analyzers will provide rapid, reliable diagnosis, and monitoring by delivering consistent, accurate results.
- The Yumizen C230 analyzer is designed for smaller laboratories, with advanced, user-friendly features.
- Yumizen C240 is a compact and cost-efficient offering, with full walk-away capabilities and advanced features for mid-sized to small labs.
- Yumizen C560 analyzer is a stand-alone floor model workhorse, offering high-end features typically found only in large, integrated systems.
Additionally, HORIBA plans to offer comprehensive and high-quality clinical chemistry reagents of the POINTE brand. The POINTE brand, started in the United States, has over 40+ years of expertise in developing reagents and distribution. The POINTE reagents have been meeting changing demands over decades, and will be paired with chemistry analyzers by HORIBA Medical.
HORIBA also contributes to the Government of India’s (GOI) push for Make in India towards industrial development, economic growth, more job creation, and a self-sustainable, self-reliant Atmanirbhar Bharat, with two dedicated manufacturing facilities at Haridwar and Nagpur.
The manufacturing facility at Haridwar initiated production in 2013 to support the growing market with quick delivery of reagents. The manufacturing facility at Nagpur started operations in 2021 and is spread across an area of 12 acres. This facility comprises of manufacturing, refurbishment, a central warehouse facility, an International Training Center, HORIBA Experience Zone, and HORIBA India Technical Institute (HITI). It is one-of-its-kind and is accredited with ISO 9001:2015, ISO 13485:2016, GMP, GLP, and CE certification.
HORIBA India has an indigenous range of open-market chemistry reagents Yumizen CR, which are highly cost-effective and high-quality reagents catering to the need of different laboratories across India.
Recently, we have started instrument manufacturing at our state-of-the-art Nagpur facility. HORIBA India would be soon introducing a new range of indigenous clinical chemistry analyzers, which would address the requirements for Tier-II and Tier-III cities, including backup chemistry support for all laboratories with high workloads.
HORIBA is vigorous in synergizing technological advancements and we shall continue to provide cutting-edge technologies to make the world a healthier and better place amidst the changing industry dynamics.